Open the WeChat WeChat official account of Shenzhen Biomedical Innovation Industrial Park, and the enterprises in the park have frequently reported good news: KM1, the first domestic oncolytic vaccinia virus product developed by Huayao Kangming Biopharmaceutical Co., Ltd., has obtained clinical approval; Yaneng Biotechnology Co., Ltd. was recognized by the Ministry of Industry and Information Technology as the fourth batch of "Little Giant" enterprises specializing in specialty and novelty; Ward Life Science and Technology Co., Ltd. won the "Shenzhen Science and Technology Anti-epidemic Major Project" …
According to the statistics of Shenzhen Enterprise Registration Bureau, by the end of July, there were 322 new biomedical enterprises in the city this year. Up to now, nearly 1,000 biomedical enterprises have gathered in Pingshan District, accounting for nearly 50% of the biomedical enterprises in the city. Recently, the reporter walked into the biomedical enterprises in Pingshan District and felt the vigorous driving force for the high-quality development of the industry.
"Industry Upstairs" creates space for industry
Entering the Shenzhen Biomedical Innovation Industrial Park in Pingshan District, more than 100 staff members are immersed in R&D and production in Keruichi (Shenzhen) Medical Technology Development Co., Ltd. Keruichi came to the park to take root in 2016, focusing on the field of minimally invasive medical interventional therapy. It has obtained the D round of financing and is in a rapid development stage. In the future, Keruichi will expand its production and operation, hoping to have more development space in the park.
Like Keruichi, many biomedical enterprises have gathered in Shenzhen to engage in research and development. What if the industrial space is insufficient? The solution is "industry goes upstairs".
Shenzhen Biomedical Innovation Industrial Park is a large-scale carrier of biomedical industry, which is controlled by Shenzhen Investment and operated by Shenfubao Group. At present, the park has introduced more than 90 scientific and technological innovative enterprises, forming an agglomeration advantage in various fields of biological segmentation. More than 100 doctors and biologists from domestic and foreign universities lead a group of innovative talents in the field of biomedical industry, and constantly achieve breakthroughs in the field of biomedical technology. In order to accelerate the introduction and cultivation of innovative bio-pharmaceutical enterprises, the park is in full swing to promote the construction of 71,000 square meters of capacity-raising projects, and combined with operational experience, innovatively proposes to explore "a new model of pharmaceutical industry going upstairs to innovate industrial space".
Among them, Building No.11 in the capacity upgrading project is a practical version of "Industrial Upstairs" for the park. The building will be a 21-storey high-rise building according to the compound standard of "factory building+office building", and it will be positioned as an industrial space integrating R&D, office and production. The industrial space has been greatly expanded, and the production of high floors can still be started. When designing the project, according to the office concept of "lower production and upper research and development", the special process requirements of enterprises in the biomedical field are met to the greatest extent.
The first floor of the project is 6 meters high, the second to fifth floors are 5.4 meters high, and the sixth and above floors are 4.5 meters high. The first floor has a bearing capacity of 1,200kg/m2, the second to third floors have a bearing capacity of 800kg/m2, and the fourth and above floors have a bearing capacity of 650kg/m2. At the same time, each building is equipped with two freight elevators with a load of 3 tons. Compared with conventional factory buildings, the "industrial upstairs" mode of high-rise factory buildings can solve the problem of scattered functional facilities due to the restrictions of comprehensive cost, site and operation, improve the production efficiency of enterprises and promote the efficient use of land resources in the park.
The innovation practice of Shenzhen Biomedical Innovation Industrial Park is a microcosm of the development of Shenzhen Investment Control Park. At present, the whole system has planned to build more than 50 industrial parks with different characteristics, with a total construction area of about 30 million square meters, which has become a "fertile soil" for the development of science and technology industries.
Research and development results solve the "stuck neck" problem
In the past few days, the reporter learned in the interview that many biomedical enterprises in Shenzhen have passed the initial stage and are advancing to a higher level of core technology to solve the "stuck neck" problem.
The Gamma Knife of Shenzhen Aowo Medical New Technology Development Co., Ltd., a big medical group, just won the gold medal of design in China Patent Award this year. The company has moved from Nanshan District to Shenzhen Biomedical Innovation Industrial Park.
Aowo’s patents that won the gold medal in design have been applied to a number of innovative products pioneered by Aowo. At present, it has treated more than one million patients worldwide, which has promoted the gamma knife category in large medical equipment to take the lead in realizing import substitution. Feng Yong, general manager of the company, said that the next step will be to build an international tumor radiotherapy industrial base according to the strategic development goal of the group in Greater Bay Area. In the next few months, we will focus on building an intelligent manufacturing base in Pingshan District, and build an integrated ecological chain of tumor diagnosis and treatment in Greater Bay Area. Recently, the latest clinical research on AST-3424, a targeted chemotherapy drug for liver cancer, was officially launched by Shenzhen Aixin Dawei Pharmaceutical Technology Co., Ltd., a company that settled in Shenzhen Biomedical Innovation Industrial Park, and began to recruit subjects in China, which means that the company has made key progress.
Entering the production R&D base of Shenzhen New Industry Biomedical Engineering Co., Ltd., R&D personnel are working hard. New industrybiologyChairman Rao Wei walked through it as usual, stopping from time to time to discuss with R&D personnel. As a patent inventor, his patent "an isoluminol derivative, its preparation method and application" has just won the silver prize of the 23rd China Patent Award. At present, the patented technology has been applied to all 154 chemiluminescence detection reagents of the company, and it has been applied since 2017, with a total sales income of 7,527.40 million yuan.
Shenzhen will focus on 20 key sub-sectors of strategic emerging industries and 8 key development directions of future industries. According to the statistics of Shenzhen Enterprise Registration Bureau, from January to June, there were 21,938 newly registered "20+8" industrial enterprises in Shenzhen. Among them, there are 20,280 enterprises belonging to 20 industrial clusters and 1,658 enterprises belonging to eight future industries. As a member of strategic emerging industries, Rao Wei said that the newindustryBio will further increase investment in R&D, extend the company’s product line from chemiluminescence immunoassay to biochemical analysis and detection of nucleic acid molecules, and accelerate the company’s intellectual property layout in the field of new technologies.
(author:Shenzhen Special Zone Daily reporter He Yong)